Further studies on the interaction between vasoactive intestinal peptide and neuroblastoma cell lines.
Pence
J C
JC
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Shorter
N A
NA
D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D004357:Drug Synergism; D005934:Glucagon / Q000494:pharmacology; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D009447:Neuroblastoma; D010446:Peptide Fragments / Q000494:pharmacology; D012633:Secretin / Q000494:pharmacology; D017337:Sermorelin; D013936:Thymidine / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D010446:Peptide Fragments; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D014212:Tretinoin; D017337:Sermorelin; D005934:Glucagon; D013007:Growth Hormone-Releasing Hormone; D013936:Thymidine